Initial therapy of HIV infection

被引:61
作者
Gallant, JE [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA
关键词
investigational drugs; initial therapy; HAART; resistance; salvageability; naive patients;
D O I
10.1016/S1386-6532(02)00024-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: The use of antiretroviral therapy has improved the quality of life and has increased the survival of HIV-infected individuals. However, the rapid rate of virus mutation and subsequent emergence of drug-resistant HIV variants threaten the longer-term efficacy of HIV treatment. The initial regimen provides the greatest chance for lasting suppression of viral load. Aims: Appropriate selection of the initial antiretroviral regimen is critical. The growing number of drug classes allows healthcare providers to individualize treatment regimens. Factors influencing the selection of first-line therapy include baseline viral load and CD4 count, drug pharmacokinetics, potency, tolerability, safety, resistance and salvageability. Characteristics likely to affect adherence, such as regimen complexity and pill burden, must also be considered, as poor adherence is the most common cause of treatment failure. Conclusion: The selection of the initial regimen requires consideration of several factors. Drugs from new classes as well as new drugs from existing classes with favorable resistance and side effect profiles are in various stages of development. Many of these drugs will enhance available options for initial therapy. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:317 / 333
页数:17
相关论文
共 84 条
  • [1] Efavirenz
    Adkins, JC
    Noble, S
    [J]. DRUGS, 1998, 56 (06) : 1055 - 1064
  • [2] In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors
    Back, NKT
    van Wijk, A
    Remmerswaal, D
    van Monfort, M
    Nijhuis, M
    Schuurman, R
    Boucher, CAB
    [J]. AIDS, 2000, 14 (01) : 101 - 102
  • [3] Balotta C, 2000, J BIOL REG HOMEOS AG, V14, P51
  • [4] Balzarini J, 1999, BIOCHEM PHARMACOL, V58, P1
  • [5] BANGSBERG DR, 2001, 8 C RETR OPP INF CHI
  • [6] Nelfinavir - An update on its use in HIV infection
    Bardsley-Elliot, A
    Plosker, GL
    [J]. DRUGS, 2000, 59 (03) : 581 - 620
  • [7] HIV-1 drug resistance in newly infected individuals
    Boden, D
    Hurley, A
    Zhang, LQ
    Cao, YZ
    Guo, Y
    Jones, E
    Tsay, J
    Ip, J
    Farthing, C
    Limoli, K
    Parkin, N
    Markowitz, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12): : 1135 - 1141
  • [8] Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
    Brinkman, K
    Smeitink, JA
    Romijn, JA
    Reiss, P
    [J]. LANCET, 1999, 354 (9184) : 1112 - 1115
  • [9] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    Carr, A
    Samaras, K
    Thorisdottir, A
    Kaufmann, GR
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1999, 353 (9170) : 2093 - 2099
  • [10] A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
    Carr, A
    Miller, J
    Law, M
    Cooper, DA
    [J]. AIDS, 2000, 14 (03) : F25 - F32